呼吸器疾患治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR5004)
◆英語タイトル:Global Respiratory Disorders Drugs Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR5004
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:93
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥499,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥748,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、呼吸器疾患治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(経口、鼻、注射剤)、用途別市場規模(病院、小売薬局)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・呼吸器疾患治療薬の市場動向
・企業の競争状況、市場シェア
・呼吸器疾患治療薬の種類別市場規模(経口、鼻、注射剤)
・呼吸器疾患治療薬の用途別市場規模(病院、小売薬局)
・呼吸器疾患治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・呼吸器疾患治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・呼吸器疾患治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・呼吸器疾患治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・呼吸器疾患治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Novartis、Sanofi、Teva Pharmaceutical、Merck & Co.、Sumitomo Dainippon Pharma、Mylan、AstraZeneca、Boehringer Ingelheim International、Vertex Pharmaceuticals Incorporated、Roche、GlaxoSmithKline)
・結論
【レポートの概要】

Market Analysis and Insights: Global Respiratory Disorders Drugs Market
The global Respiratory Disorders Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Respiratory Disorders Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Respiratory Disorders Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Respiratory Disorders Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Respiratory Disorders Drugs market.

Global Respiratory Disorders Drugs Scope and Market Size
Respiratory Disorders Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Respiratory Disorders Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral
Nasal
Injectable

Segment by Application
Hospital
Retail Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Sanofi
Teva Pharmaceutical
Merck & Co.
Sumitomo Dainippon Pharma
Mylan
AstraZeneca
Boehringer Ingelheim International
Vertex Pharmaceuticals Incorporated

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Disorders Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral
1.2.3 Nasal
1.2.4 Injectable
1.3 Market by Application
1.3.1 Global Respiratory Disorders Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Respiratory Disorders Drugs Market Perspective (2016-2027)
2.2 Respiratory Disorders Drugs Growth Trends by Regions
2.2.1 Respiratory Disorders Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Respiratory Disorders Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Respiratory Disorders Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Respiratory Disorders Drugs Industry Dynamic
2.3.1 Respiratory Disorders Drugs Market Trends
2.3.2 Respiratory Disorders Drugs Market Drivers
2.3.3 Respiratory Disorders Drugs Market Challenges
2.3.4 Respiratory Disorders Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Respiratory Disorders Drugs Players by Revenue
3.1.1 Global Top Respiratory Disorders Drugs Players by Revenue (2016-2021)
3.1.2 Global Respiratory Disorders Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Respiratory Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Respiratory Disorders Drugs Revenue
3.4 Global Respiratory Disorders Drugs Market Concentration Ratio
3.4.1 Global Respiratory Disorders Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Disorders Drugs Revenue in 2020
3.5 Respiratory Disorders Drugs Key Players Head office and Area Served
3.6 Key Players Respiratory Disorders Drugs Product Solution and Service
3.7 Date of Enter into Respiratory Disorders Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Respiratory Disorders Drugs Breakdown Data by Type
4.1 Global Respiratory Disorders Drugs Historic Market Size by Type (2016-2021)
4.2 Global Respiratory Disorders Drugs Forecasted Market Size by Type (2022-2027)

5 Respiratory Disorders Drugs Breakdown Data by Application
5.1 Global Respiratory Disorders Drugs Historic Market Size by Application (2016-2021)
5.2 Global Respiratory Disorders Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Respiratory Disorders Drugs Market Size (2016-2027)
6.2 North America Respiratory Disorders Drugs Market Size by Type
6.2.1 North America Respiratory Disorders Drugs Market Size by Type (2016-2021)
6.2.2 North America Respiratory Disorders Drugs Market Size by Type (2022-2027)
6.2.3 North America Respiratory Disorders Drugs Market Size by Type (2016-2027)
6.3 North America Respiratory Disorders Drugs Market Size by Application
6.3.1 North America Respiratory Disorders Drugs Market Size by Application (2016-2021)
6.3.2 North America Respiratory Disorders Drugs Market Size by Application (2022-2027)
6.3.3 North America Respiratory Disorders Drugs Market Size by Application (2016-2027)
6.4 North America Respiratory Disorders Drugs Market Size by Country
6.4.1 North America Respiratory Disorders Drugs Market Size by Country (2016-2021)
6.4.2 North America Respiratory Disorders Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Respiratory Disorders Drugs Market Size (2016-2027)
7.2 Europe Respiratory Disorders Drugs Market Size by Type
7.2.1 Europe Respiratory Disorders Drugs Market Size by Type (2016-2021)
7.2.2 Europe Respiratory Disorders Drugs Market Size by Type (2022-2027)
7.2.3 Europe Respiratory Disorders Drugs Market Size by Type (2016-2027)
7.3 Europe Respiratory Disorders Drugs Market Size by Application
7.3.1 Europe Respiratory Disorders Drugs Market Size by Application (2016-2021)
7.3.2 Europe Respiratory Disorders Drugs Market Size by Application (2022-2027)
7.3.3 Europe Respiratory Disorders Drugs Market Size by Application (2016-2027)
7.4 Europe Respiratory Disorders Drugs Market Size by Country
7.4.1 Europe Respiratory Disorders Drugs Market Size by Country (2016-2021)
7.4.2 Europe Respiratory Disorders Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Respiratory Disorders Drugs Market Size (2016-2027)
8.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Type
8.2.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Respiratory Disorders Drugs Market Size by Application
8.3.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Respiratory Disorders Drugs Market Size by Region
8.4.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Respiratory Disorders Drugs Market Size (2016-2027)
9.2 Latin America Respiratory Disorders Drugs Market Size by Type
9.2.1 Latin America Respiratory Disorders Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Respiratory Disorders Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Respiratory Disorders Drugs Market Size by Type (2016-2027)
9.3 Latin America Respiratory Disorders Drugs Market Size by Application
9.3.1 Latin America Respiratory Disorders Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Respiratory Disorders Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Respiratory Disorders Drugs Market Size by Application (2016-2027)
9.4 Latin America Respiratory Disorders Drugs Market Size by Country
9.4.1 Latin America Respiratory Disorders Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Respiratory Disorders Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Respiratory Disorders Drugs Market Size (2016-2027)
10.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Type
10.2.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Respiratory Disorders Drugs Market Size by Application
10.3.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Respiratory Disorders Drugs Market Size by Country
10.4.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Respiratory Disorders Drugs Introduction
11.1.4 Novartis Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Respiratory Disorders Drugs Introduction
11.2.4 Sanofi Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Teva Pharmaceutical
11.3.1 Teva Pharmaceutical Company Details
11.3.2 Teva Pharmaceutical Business Overview
11.3.3 Teva Pharmaceutical Respiratory Disorders Drugs Introduction
11.3.4 Teva Pharmaceutical Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.3.5 Teva Pharmaceutical Recent Development
11.4 Merck & Co.
11.4.1 Merck & Co. Company Details
11.4.2 Merck & Co. Business Overview
11.4.3 Merck & Co. Respiratory Disorders Drugs Introduction
11.4.4 Merck & Co. Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.4.5 Merck & Co. Recent Development
11.5 Sumitomo Dainippon Pharma
11.5.1 Sumitomo Dainippon Pharma Company Details
11.5.2 Sumitomo Dainippon Pharma Business Overview
11.5.3 Sumitomo Dainippon Pharma Respiratory Disorders Drugs Introduction
11.5.4 Sumitomo Dainippon Pharma Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.5.5 Sumitomo Dainippon Pharma Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Respiratory Disorders Drugs Introduction
11.6.4 Mylan Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.6.5 Mylan Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Respiratory Disorders Drugs Introduction
11.7.4 AstraZeneca Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.7.5 AstraZeneca Recent Development
11.8 Boehringer Ingelheim International
11.8.1 Boehringer Ingelheim International Company Details
11.8.2 Boehringer Ingelheim International Business Overview
11.8.3 Boehringer Ingelheim International Respiratory Disorders Drugs Introduction
11.8.4 Boehringer Ingelheim International Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.8.5 Boehringer Ingelheim International Recent Development
11.9 Vertex Pharmaceuticals Incorporated
11.9.1 Vertex Pharmaceuticals Incorporated Company Details
11.9.2 Vertex Pharmaceuticals Incorporated Business Overview
11.9.3 Vertex Pharmaceuticals Incorporated Respiratory Disorders Drugs Introduction
11.9.4 Vertex Pharmaceuticals Incorporated Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.9.5 Vertex Pharmaceuticals Incorporated Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Respiratory Disorders Drugs Introduction
11.10.4 Roche Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.10.5 Roche Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Respiratory Disorders Drugs Introduction
11.11.4 GlaxoSmithKline Revenue in Respiratory Disorders Drugs Business (2016-2021)
11.11.5 GlaxoSmithKline Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 呼吸器疾患治療薬の世界市場規模・現状・予測2021年-2027年(Global Respiratory Disorders Drugs Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。